Intracranial Red Light Treatment Device For Chronic Pain

• US 20100198316A1
• Filed: 02/04/2009
• Published: 08/05/2010
• Est. Priority Date: 02/04/2009
• Status: Abandoned Application

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Inventors: Toselli, Richard, DiMauro, Thomas M., Fisher, Michael A., Lilienfeld, Sean
• Application Number:
  US12/365,371
• Publication Number:
  US 20100198316A1
• Time in Patent Office: Days
• US Class Current: 607/88
• CPC Class Codes: A61N 1/3787 from an external energy source
• CPC Class Codes: A61N 2005/063 comprising light transmitting means, e.g. optical fibres
• CPC Class Codes: A61N 2005/0651 Diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body

Abstract

Placement of a silicone tube in the cerebral aqueduct and the transmission of red light through it, resulting in the irradiation and consequent biostimulation of the adjacent periaqueductal gray, thereby causing the release of endorphins therefrom and pain relief.

Claims

1. A method of treating a patient having chronic pain, comprising the steps of:

a) providing a optical wave guide having a proximal end portion and a distal end portion having a translucent light diffuser attached thereto;

b) implanting the translucent light diffuser into the patient'"'"'s cerebral aqueduct, and

c) delivering light through the optical wave guide and translucent light diffuser to irradiate at least a portion of a periaqueductal gray with an effective amount of light.

2. The method of claim 1 wherein the diameter of the translucent light diffuser is at least two times the diameter of the cerebral aqueduct.

3. The method of claim 1 wherein the diameter of the translucent light diffuser is at least three times the diameter of the cerebral aqueduct.

4. The method of claim 1 wherein the diameter of the translucent light diffuser has a tube shape.

5. The method of claim 1 wherein the length of the translucent light diffuser is at least 25% of the length of the cerebral aqueduct.

6. The method of claim 1 wherein the length of the translucent light diffuser is at least 50% of the length of the cerebral aqueduct.

7. The method of claim 1 wherein the length of the translucent light diffuser is at least 75% of the length of the cerebral aqueduct.

8. The method of claim 1 wherein the effective amount of light causes release of endorphins from the periaqueductal gray.

9. The method of claim 1 wherein the effective amount of light is delivered in an energy density of between 1 J/cm² and 10 J/cm².

10. The method of claim 1 wherein the effective amount of light is delivered in a wavelength of between 600 nm and 900 nm.

11. An intracranial light delivery system, comprising:

a) a light source,

b) an optical wave guide having a proximal end connected to the light source and a distal end, and

c) a translucent light diffuser connected to the distal end of the optical wave guide.

12. The system of claim 11 wherein the translucent light diffuser comprises silicone.

13. The system of claim 11 wherein the translucent light diffuser comprises antibiotics.

14. The system of claim 11 wherein the translucent light diffuser comprises features that increase the radial transmission of light through its outer surface.

15. The system of claim 11 wherein the translucent light diffuser comprises diffractive elements embedded within the translucent tube in order to diffraction light traveling down the length of the light diffuser to exit the light diffuser in a radial direction.

16. The system of claim 11 wherein the diffractive elements comprise metallic particles.

17. The system of claim 11 wherein the translucent light diffuser comprises an outer surface that is etched in order to diffract light that is traveling down the length of the light diffuser to exit the light diffuser in a radial direction.

18. The system of claim 11 wherein the translucent light diffuser comprises an outer surface that is coated with a reflective coating to deflect axially-traveling light back into the light diffuser.

19. The system of claim 11 wherein the translucent light diffuser comprises an inner surface that is coated with a reflective coating to deflect light back into the light diffuser.

20. The system of claim 11 wherein the translucent light diffuser comprises an outer surface that is coated with an adhesive.

21. The system of claim 11 wherein the translucent light diffuser comprises a tube shape.

22. The system of claim 11 wherein the translucent light diffuser comprises a helical shape.

23. The system of claim 11 wherein the translucent light diffuser comprises a standoff.

24. A method of treating a patient having chronic pain, comprising the steps of:

a) endoscopically implanting a translucent light diffuser into the patient'"'"'s cerebral aqueduct, and

b) delivering light through the translucent light diffuser to irradiate at least a portion of a periaqueductal grey with an effective amount of light.

25. The method of claim 24 further comprising the step of:

inserting a rigid neuroendoscope into the lateral ventricle.

26. The method of claim 25 further comprising the step of:

advancing the endoscope into the third ventricle.

27. The method of claim 26 further comprising the step of:

advancing the endoscope into the cerebral aqueduct.

31. A method of treating a patient having chronic pain, comprising the steps of:

a) providing a optical wave guide having a distal end portion having a translucent light diffuser attached thereto, and

b) endoscopically implanting the translucent light diffuser in the patient'"'"'s periaqueductal gray.

41. A method of treating a patient having chronic pain, comprising the steps of:

a) providing a rigid neuroendoscope holding a translucent light diffuser having a optical wave guide attached thereto, and

b) inserting the neuroendoscope into the lateral ventricle.

42. The method of claim 41 further comprising the step of:

c) advancing the endoscope into the third ventricle.

43. The method of claim 42 further comprising the step of:

d) advancing the endoscope into the cerebral aqueduct.

44. The method of claim 43 further comprising the step of:

e) implanting the translucent light diffuser in the patient'"'"'s cerebral aqueduct.

45. An intracranial light delivery system, comprising:

a) an energy supply source,

b) a controlling logical module,

c) connecting wires, and

d) a potted light-emitting diode array

46. The system of claim 45 wherein the light-emitting diode array is potted in such a configuration to place the diodes in discrete locations to illuminate the desired portion of the cerebral aqueduct.

47. The system of claim 45 wherein the light-emitting diode array contains at least one photo diode to measure at least one local light energy level.

48. The system of claim 45 wherein individual potted light-emitting diodes illuminate discrete segments of the cerebral aqueduct at different times.

49. The system of claim 45 wherein the potted light-emitting diodes are arranged in such a way as to create a mechanical interference fit with the local tissue contours.

50. The system of claim 45 wherein at least a section of the potting material is partially flexible post-implantation.

51. The system of claim 45 wherein at least a section of the potting material becomes substantially rigid during the post-implantation period.

52. The system of claim 45 wherein at least a portion of the potting material is translucent

53. The system of claim 45 wherein at least a portion of the potting material serves to diffuse the photonic energy being broadcast from the embedded light-emitting diodes.